Bayer CropScience Ltd (NSE: BAYERCROP) – In-Depth Equity Research Report

Company Overview

Bayer CropScience Ltd is a leading Indian agrochemical company and a subsidiary of the global Bayer AG (Germany). Listed on both the National Stock Exchange (NSE: BAYERCROP) and the Bombay Stock Exchange (BSE: 506285), the company is engaged in the Agri Care business, which primarily includes the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products along with corn seeds.

The Bayer group launched its Indian operations in 1958 by setting up an agrochemical manufacturing unit. Today, the company is a prominent player in India's crop protection and seeds industry. The promoter group holds a 71.44% stake in the company, reflecting strong parent commitment to the Indian market. Bayer CropScience also trades in seeds on behalf of Bayer Bioscience Pvt Ltd and operates through its single reporting segment — Agri Care.

The company's product portfolio spans across multiple crop protection categories including insecticides for pest management, fungicides for disease control, herbicides for weed management, and hybrid seeds for improved agricultural yields. It serves millions of farmers across India through a vast distribution network.

Key Financial Highlights

Market Data & Valuation Metrics

The stock is currently trading 30.9% below its 52-week high of ₹6,540 and just 6.0% above its 52-week low of ₹4,273, indicating significant price correction from peak levels. The TTM P/E ratio of 29.41 is higher than the sector average P/E of 24.29, suggesting the stock commands a premium relative to peers. The price-to-book ratio of 7.11x is notably above the sector average of 3.47x, reflecting the brand value and parentage premium.

Quarterly Financial Performance

Quarterly Income Statement (₹ Cr)

Key Quarterly Observations

The quarterly data reveals a highly seasonal business with Q1 (April-June) consistently being the strongest quarter due to the Kharif cropping season. For instance:

• Q1 FY26 (Jun 2025) recorded the highest revenue of ₹1,933.30 Cr and net profit of ₹278.70 Cr with an EPS of ₹62.01, driven by peak Kharif season demand.
• Q3 FY25 (Dec 2024) was the weakest quarter with revenue of just ₹1,089.60 Cr and net profit of only ₹34.20 Cr (EPS ₹7.61), reflecting the typical Rabi season slowdown.

Year-over-year quarterly comparisons show:

• Q4 FY26 (Mar 2026): Net profit rose 13.12% YoY to ₹162.10 Cr, with sales up 5.20% to ₹1,100.80 Cr (standalone).
• Q3 FY26 (Dec 2025): Net profit surged 179.82% YoY to ₹95.70 Cr, with sales up 4.62% to ₹1,106.20 Cr (standalone).
• Q2 FY26 (Sep 2025): Net profit grew 12.03% YoY to ₹152.70 Cr, though sales declined 10.60% to ₹1,553.40 Cr (standalone) due to adverse weather conditions.
• Q1 FY26 (Jun 2025): Net profit increased 9.64% YoY to ₹278.70 Cr with revenue growing 16.54% to ₹1,933.30 Cr.

The trailing twelve months (TTM) revenue stands at approximately ₹5,770 Cr while TTM net profit totals approximately ₹689.20 Cr, yielding a TTM EPS of ₹153.35.

Annual Financial Performance

Compounded Growth Rates

The 1-year stock price return of -20% is concerning and reflects the significant correction from the 52-week high of ₹6,540. The stock has underperformed the broader market significantly over the past year. However, the TTM profit growth of 15% outpacing sales growth of 9% indicates improving operational efficiency.

Annual Revenue & EPS Trend

From the available data, the company's annual revenue trajectory shows:

The revenue has shown a steady upward trend, growing from approximately ₹4,060 Cr in FY23 to an estimated ₹5,770 Cr in FY26 TTM. However, EPS has been volatile — declining from ₹168.71 in FY23 to ₹126.38 in FY25 before recovering to ₹153.35 in FY26 TTM. This volatility is largely attributable to margin pressures from rising input costs and inventory challenges due to adverse weather.

Dividend History

Bayer CropScience has maintained a consistent dividend payment track record, reflecting the parent company's commitment to returning value to minority shareholders:

The total dividend for FY26 (interim ₹90 + final ₹60) amounts to ₹150 per share, which at the current price of ₹4,529 translates to a dividend yield of approximately 3.31%. This is among the highest dividend yields in the Indian agrochemical sector. The company paid ₹125 per share in FY25 (interim ₹90 + final ₹35) and ₹140 per share in FY24 (interim ₹105 + final ₹35).

Balance Sheet & Cash Flow Analysis

Balance Sheet Snapshot (₹ Cr)

Note: Screener.in shows only historical balance sheet data (2005-2006) for non-logged-in users. The current book value per share of ₹84.5 indicates total equity of approximately ₹379 Cr on the current share capital base of ₹44.8 Cr (face value ₹10).

Cash Flow Metrics (₹ Cr)

Financial Ratios

The ROCE of 20.1% (current) indicates efficient capital utilization. The company has maintained a strong return profile despite being in a cyclical industry. The ROE of 15.8% is respectable, though the high price-to-book ratio of 7.11x suggests the market values the company significantly above its book value.

Shareholding Pattern

Current Shareholding (March 2026)

Promoter Holding Trend

The promoter holding has remained rock-solid at 71.44% from Jun 2023 through Mar 2026, reflecting Bayer AG's unwavering commitment to the Indian operations. The pledged promoter holding is negligible/zero, which is a strong positive signal.

FII Trend

Foreign institutional holding has shown a gradual upward trend:

• Mar 2024: 3.62%
• Mar 2025: 3.49%
• Dec 2025: 3.84%
• Mar 2026: 3.89%

The increase in FII holding from 3.49% to 3.89% over the past year indicates growing foreign interest despite the stock's price decline.

DII Trend

Domestic institutional holding has shown some mild reduction:

• Mar 2024: 12.80%
• Mar 2025: 11.56%
• Mar 2026: 11.89%

Retail Holding

Retail and public holding stands at 12.79% as of March 2026, with the total number of shareholders at 55,795 — up from 45,852 in March 2024, indicating growing retail participation.

Mutual Fund Holdings

Notable mutual funds holding Bayer CropScience include:

• Quant Small Cap Fund — Market-cap held: 2.44%, Weight: 1.63%
• Nippon India Small Cap Fund — Market-cap held: 1.13%, Weight: 0.37%
• DSP Small Cap Fund — Significant holdings
• Nippon India Growth Mid Cap Fund — Notable position
• Aditya Birla Sun Life Large Cap Fund — Exposure in portfolio

Peer Comparison

Agrochemical Sector Peer Analysis

Note: The consolidated P/E of 412.79 for Bayer CropScience appears elevated due to one-time/extraordinary items in the consolidated financials. On a TTM standalone basis, the P/E is a more reasonable 29.41.

Peer Analysis Insights

1. Market Position: Bayer CropScience is the 4th largest agrochemical company in India by market capitalization (₹20,322 Cr), behind UPL (₹54,053 Cr), P I Industries (₹40,848 Cr), and Sumitomo Chemicals (₹24,015 Cr).

2. Dividend Leader: Bayer CropScience offers the highest dividend yield (2.76%) among all peers, significantly above the sector average of 2.13%.

3. Strong ROCE: With an ROCE of 20.08%, Bayer ranks among the top 3 in capital efficiency, behind Sharda Cropchem (30.37%) and Dhanuka Agritech (23.97%).

4. Profit Growth: Bayer reported the highest quarterly profit growth (125.16%) among peers in the latest quarter, suggesting strong recovery momentum.

5. Valuation Premium: On a standalone TTM P/E basis (29.41), Bayer trades at a slight premium to UPL (28.60) but below Sumitomo (43.31), reflecting its mid-tier valuation positioning.

Industry Analysis & Growth Drivers

Indian Agrochemical Industry

The Indian agrochemical market is valued at approximately $8-10 billion and is expected to grow at a CAGR of 8-10% over the next five years. Key growth drivers include:

1. Rising Food Demand: India's growing population (1.4+ billion) necessitates higher agricultural productivity, driving demand for crop protection chemicals.

2. Government Initiatives: Programs like PM-KISAN, crop insurance schemes, and minimum support price (MSP) increases support farmer incomes and spending on agrochemicals.

3. Climate Change: Increasing pest infestations and disease patterns due to climate change are driving higher agrochemical usage.

4. Shift to Branded Products: Farmers are increasingly shifting from generic/unbranded products to branded, scientifically-backed solutions.

5. Export Opportunities: India is emerging as a major agrochemical manufacturing hub, with companies increasingly exporting to global markets.

Bayer CropScience's Competitive Advantages

1. Global Parentage: Backed by Bayer AG, one of the world's largest life science companies, providing access to cutting-edge R&D, global product pipeline, and best practices.

2. Strong Brand Recognition: Bayer is one of the most trusted brands among Indian farmers, with decades of market presence since 1958.

3. Diversified Product Portfolio: The company offers a comprehensive range of crop protection solutions across insecticides, fungicides, herbicides, and seeds.

4. Robust Distribution Network: A vast network of active distributors and dealers across India ensures deep market penetration.

5. Innovation Focus: The company invests significantly in R&D, with innovation contributing meaningfully to total business.

6. Better Life Farming (BLF) Centers: Bayer operates BLF centers across India to provide farmers with agronomic advice and solutions.

Growth Drivers & Challenges

Growth Drivers (Score: 6/10)

1. Strong Financial Performance: The company has reported a 6% increase in Profit Before Tax and a nearly 12.5% growth in recent quarters, indicating improving profitability.

2. Successful Product Launches: New products like Council Activ have quickly gained market traction, contributing to revenue growth.

3. Strategic Portfolio Management: The company is prioritizing a profitable product portfolio, emphasizing divestments of less critical assets to focus on high-margin products.

4. Kharif Season Demand: The upcoming Kharif season (June-September) typically drives 40-45% of annual revenue, and favorable monsoon forecasts could boost FY27 performance.

5. Seeds Business Growth: The corn seeds business is expanding, with Bayer holding a strong position in the hybrid seeds market.

6. Digital Agriculture: Bayer is increasingly leveraging digital platforms to reach farmers and provide precision agriculture solutions.

Challenges (Score: 5/10)

1. Sales and Inventory Challenges: The company faced significant challenges in sales and inventory management due to adverse weather conditions, which impacted volumes.

2. Margin Pressures: Rising input prices and a limited ability to pass on cost increases are compressing margins.

3. Accounts Receivable Issues: The company faced unprecedented accounts receivable collection issues in FY24-25, which are atypical for the business.

4. Seasonality Risk: The highly seasonal nature of the business creates quarterly earnings volatility, with Q3 typically being the weakest.

5. Competitive Pressure: Intense competition from both domestic players and other MNCs is putting pressure on market share and pricing.

6. Regulatory Risk: Changes in pesticide regulations and potential bans on certain chemicals could impact product portfolios.

Valuation Analysis

Current Valuation Metrics

Valuation Assessment

The stock appears fairly valued to slightly expensive based on the following analysis:

1. P/E Premium: The 21% premium over sector average P/E is justified by Bayer's superior brand, global parentage, consistent profitability, and strong dividend track record.

2. High P/B Ratio: The 7.11x price-to-book reflects the asset-light nature of the business and the significant intangible value of the Bayer brand. The book value of ₹84.5 per share significantly understates the company's earning power.

3. Dividend Yield: While the TTM dividend yield of 1.33% appears low, the total FY26 dividend of ₹150 per share (including the recently recommended ₹60 final dividend) yields 3.31%, which is attractive.

4. Analyst Consensus: According to TickerTape, 50% of analysts recommend a buy on the stock, from a pool of 8 analysts covering the company.

Fair Value Estimation

Using a P/E-based valuation approach:

• TTM EPS: ₹153.35
• At sector average P/E of 24.29: Fair value = ₹3,725
• At 10% premium P/E of 26.72: Fair value = ₹4,097
• At 20% premium P/E of 29.15: Fair value = ₹4,469

The current price of ₹4,529 suggests the stock is trading at fair value when applying a modest premium for its quality attributes. However, the forecast EPS growth could push fair value higher if the company sustains its recent profit momentum.

Technical Analysis Summary

Based on the TickerTape scorecard:

• Performance: Low — Hasn't fared well, amongst the low performers
• Valuation: High — Seems to be overvalued vs the market average
• Growth: Low — Lagging behind the market in financials growth
• Profitability: High — Showing good signs of profitability & efficiency
• Entry Point: Good — The stock is underpriced and not in the overbought zone
• Fundamentals: Current price is less than intrinsic value
• Technicals: Good time to consider; stock is not in the overbought zone
• Red Flags: Low — No red flags found
• Risk: Low Risk — Stock is 1.78x as volatile as Nifty
• Promoter Pledged Holding: Insignificant (essentially zero)

The stock has returned 17.75% over the past year (Jun 2025 to Jun 2026) as per TickerTape's price comparison, outperforming UPL (0.37%) but underperforming the broader market.

Share Price Forecast

TickerTape Forecast (Jun 2027)

EPS Forecast (Mar 2027)

Revenue Forecast (Mar 2027)

Risk Factors

1. Monsoon Dependency: The agrochemical business is heavily dependent on monsoon rainfall. Deficient or excess rainfall can significantly impact demand.

2. Raw Material Costs: Agrochemical manufacturing depends on petrochemical-based raw materials, making it vulnerable to crude oil price fluctuations.

3. Regulatory Changes: Government policies on pesticide usage, import duties, and environmental regulations can impact business operations.

4. Parent Company Strategy: As a subsidiary of Bayer AG, strategic decisions made at the parent level (including global restructuring) could impact Indian operations.

5. Currency Risk: Import of raw materials exposes the company to INR/USD exchange rate fluctuations.

6. Competitive Intensity: The Indian agrochemical market is highly competitive with both domestic and multinational players vying for market share.

7. Climate Change: Unpredictable weather patterns can disrupt crop cycles and agrochemical demand.

8. Debt Concerns: The company may be capitalizing interest costs as flagged by Screener.in, which could understate the true cost of borrowing.

Investment Thesis

Bull Case

1. Best-in-class parentage with access to Bayer AG's global R&D and product pipeline
2. Strong dividend yield (3.31% on FY26 dividends) provides downside protection
3. Consistent promoter holding (71.44%) with zero pledging
4. Improving profitability with TTM profit growth of 15%
5. No red flags identified by TickerTape's screening tools
6. Favorable entry point — stock not in overbought zone, trading near 52-week lows
7. Growing seeds business diversifying revenue streams

Bear Case

1. Premium valuation — P/E of 29.41x vs sector average of 24.29x
2. Stock down 20% in last year — momentum is negative
3. Revenue growth slowing — challenges in sales and inventory management
4. Margin pressure from rising input costs
5. Seasonal earnings volatility makes quarterly predictions difficult
6. Accounts receivable issues in FY24-25 raise working capital concerns
7. Limited float — only 28.56% public holding can create liquidity constraints

Conclusion

Bayer CropScience Ltd represents a quality play on the Indian agrochemical sector with strong fundamentals, consistent dividends, and the backing of a global parent. The company's ROCE of 20.1%, ROE of 15.8%, and consistent dividend payments make it an attractive option for long-term investors seeking exposure to India's agricultural growth story.

However, the premium valuation (P/E 29.41x vs sector 24.29x) and recent underperformance (stock down 20% in 1 year) suggest that investors should wait for a better entry point or accumulate gradually on dips. The dividend yield of 3.31% (based on FY26 payouts) provides a reasonable margin of safety.

For growth investors, the stock may underperform in the near term due to margin pressures and seasonal challenges. For income investors, the consistent dividend track record and high yield make it an attractive defensive bet. For value investors, the current price appears close to fair value, with limited upside based on conservative P/E assumptions.

Recommendation: HOLD / Accumulate on dips — The stock is a quality asset but needs better entry pricing for fresh investments. Existing holders should continue holding for dividends and long-term capital appreciation.